| |
| |
|
| Insider
Information: |
Weiss Michael S |
| Relationship: |
Director |
| City: |
Berkeley Heights |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
16,329,233 |
|
|
Indirect Shares
|
14,546,388 |
|
|
| Direct
Value |
$207,679,882 |
|
|
|
Indirect Value
|
$228,994,301 |
|
|
| Total
Shares |
30,875,621 |
|
|
| Total
Value |
$436,674,183 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
2
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
1
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
 -2.8%
|
-135.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
10% Owner |
2010-05-10 |
1,320,418 |
2003-11-21 |
0 |
Premium* |
|
|
Genta Inc De |
GNTAQ |
Director |
2005-08-05 |
537,238 |
2004-07-14 |
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
Director |
2008-08-22 |
25,000 |
|
0 |
Premium* |
|
|
TG Therapeutics Inc |
TGTX |
CEO |
2024-01-06 |
13,074,929 |
2020-06-22 |
14,434,214 |
Premium* |
|
|
Fortress Biotech, Inc. |
FBIO |
See Remarks, Director,... |
2024-01-01 |
1,346,985 |
2013-12-19 |
0 |
Premium* |
|
|
Checkpoint Therapeutics, Inc. |
CKPT |
Director |
2017-06-15 |
0 |
2024-05-14 |
112,174 |
Premium* |
|
|
Avenue Therapeutics, Inc. |
ATXI |
Director |
2018-08-07 |
24,663 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
126 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| FBIO |
Fortress Biotech, Inc. |
Exec. VC - Strategic Dev. |
• • – |
2014-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,958,692 |
5,938,038 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2014-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
268,603 |
8,389,376 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
337,257 |
8,726,633 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2015-12-31 |
4/A |
A |
$0.00 |
$0 |
D/D |
672,343 |
9,398,976 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2015-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
6,723,443 |
9,398,976 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
Exec. VC - Strategic Dev. |
• • • |
2016-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
510,434 |
7,448,472 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2016-09-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
328,764 |
9,455,662 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • • |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
I/I |
693,750 |
10,145,917 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • • |
2017-01-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,381,866) |
6,073,796 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • • |
2017-01-01 |
4 |
A |
$0.00 |
$0 |
I/I |
2,960,000 |
9,033,796 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • • |
2017-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
418,371 |
9,452,167 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
Exec. VC - Strategic Dev. |
• • • |
2017-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
552,698 |
8,001,170 |
0 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2017-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
10,000 |
10,000 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• – – |
2017-06-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
350,000 |
9,795,917 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• – – |
2017-06-19 |
4 |
A |
$0.00 |
$0 |
I/I |
834,877 |
10,630,794 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
EXECUTIVE VICE CHAIRMAN |
• • • |
2018-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
586,428 |
8,587,598 |
0 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
I/I |
16,448 |
26,448 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• – – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
I/I |
1,018,011 |
11,648,805 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
EXECUTIVE VICE CHAIRMAN |
• • • |
2018-07-03 |
4 |
A |
$0.00 |
$0 |
D/D |
164,473 |
8,752,071 |
0 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
14,663 |
24,663 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
EXECUTIVE VICE CHAIRMAN |
• • • |
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
648,204 |
9,400,275 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
I/I |
1,179,380 |
12,828,185 |
0 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
I/I |
11,442 |
37,890 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
EXECUTIVE VICE CHAIRMAN |
• • • |
2020-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
801,536 |
10,201,811 |
0 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
I/I |
24,390 |
62,280 |
0 |
- |
|
126 Records found
|
|
Page 2 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
